Literature DB >> 6419313

Heterogeneity and reduction in pulmonary clearance of mucoid Pseudomonas aeruginosa.

J R Govan, J A Fyfe, N R Baker.   

Abstract

Mucoid, alginate-producing Pseudomonas aeruginosa isolated from patients with cystic fibrosis were studied to determine the extent of heterogeneity of the isolates within individual sputa. Considerable heterogeneity involving cultural requirements for mucoid colonial growth was observed, and sensitivity to the beta-lactam antibiotic carbenicillin was also variable. For determining if the presence of alginate increased pulmonary survival of the bacteria, groups of rats were infected by transtracheal instillations of equivalent numbers of mucoid or nonmucoid P. aeruginosa, and survival was measured as the percentage of inoculum colony-forming units cultured from lung homogenates. Increased pulmonary survival of mucoid P. aeruginosa was observed in animals killed 3 hr or 6 hr after infection with unwashed bacteria. No difference in survival between mucoid and nonmucoid cells was observed when bacteria were washed prior to instillation. It was concluded that a single mucoid colony isolated from a sputum does not fully represent the population of mucoid P. aeruginosa within the patient and that pulmonary killing of mucoid P. aeruginosa can be less efficient than that for nonmucoid strains.

Entities:  

Mesh:

Year:  1983        PMID: 6419313     DOI: 10.1093/clinids/5.supplement_5.s874

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  10 in total

1.  Use of slime dispersants to promote antibiotic penetration through the extracellular polysaccharide of mucoid Pseudomonas aeruginosa.

Authors:  C A Gordon; N A Hodges; C Marriott
Journal:  Antimicrob Agents Chemother       Date:  1991-06       Impact factor: 5.191

2.  DNA sequence and expression analysis of algP and algQ, components of the multigene system transcriptionally regulating mucoidy in Pseudomonas aeruginosa: algP contains multiple direct repeats.

Authors:  W M Konyecsni; V Deretic
Journal:  J Bacteriol       Date:  1990-05       Impact factor: 3.490

Review 3.  Rational parameters for antibiotic therapy in patients with cystic fibrosis.

Authors:  J R Govan; C Doherty; S Glass
Journal:  Infection       Date:  1987 Jul-Aug       Impact factor: 3.553

4.  A procaryotic regulatory factor with a histone H1-like carboxy-terminal domain: clonal variation of repeats within algP, a gene involved in regulation of mucoidy in Pseudomonas aeruginosa.

Authors:  V Deretic; W M Konyecsni
Journal:  J Bacteriol       Date:  1990-10       Impact factor: 3.490

5.  Microbial pathogenesis in cystic fibrosis: pulmonary clearance of mucoid Pseudomonas aeruginosa and inflammation in a mouse model of repeated respiratory challenge.

Authors:  H Yu; M Hanes; C E Chrisp; J C Boucher; V Deretic
Journal:  Infect Immun       Date:  1998-01       Impact factor: 3.441

Review 6.  Microbiology of airway disease in patients with cystic fibrosis.

Authors:  P H Gilligan
Journal:  Clin Microbiol Rev       Date:  1991-01       Impact factor: 26.132

7.  Comparison of methods to test antibiotic combinations against heterogeneous populations of multiresistant Pseudomonas aeruginosa from patients with acute infective exacerbations in cystic fibrosis.

Authors:  Juliet E Foweraker; Christian R Laughton; Derek F Brown; Diana Bilton
Journal:  Antimicrob Agents Chemother       Date:  2009-08-24       Impact factor: 5.191

8.  Quantitation of adherence of mucoid and nonmucoid Pseudomonas aeruginosa to hamster tracheal epithelium.

Authors:  H Marcus; N R Baker
Journal:  Infect Immun       Date:  1985-03       Impact factor: 3.441

9.  Dampening Host Sensing and Avoiding Recognition in Pseudomonas aeruginosa Pneumonia.

Authors:  Cristina Cigana; Nicola Ivan Lorè; Maria Lina Bernardini; Alessandra Bragonzi
Journal:  J Biomed Biotechnol       Date:  2011-07-14

Review 10.  Biology of Pseudomonas aeruginosa in relation to pulmonary infection in cystic fibrosis.

Authors:  T L Pitt
Journal:  J R Soc Med       Date:  1986       Impact factor: 18.000

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.